Fjarde AP Fonden Fourth Swedish National Pension Fund Sells 36,400 Shares of Kenvue Inc. $KVUE

Fjarde AP Fonden Fourth Swedish National Pension Fund decreased its position in shares of Kenvue Inc. (NYSE:KVUE) by 12.2% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 263,135 shares of the company’s stock after selling 36,400 shares during the quarter. Fjarde AP Fonden Fourth Swedish National Pension Fund’s holdings in Kenvue were worth $4,539,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also made changes to their positions in the company. Highbridge Capital Management LLC bought a new position in shares of Kenvue during the 4th quarter worth $20,258,000. Nuance Investments LLC grew its position in shares of Kenvue by 294.4% during the 4th quarter. Nuance Investments LLC now owns 2,813,985 shares of the company’s stock worth $48,541,000 after buying an additional 2,100,583 shares in the last quarter. Vise Technologies Inc. grew its position in shares of Kenvue by 110.6% during the 4th quarter. Vise Technologies Inc. now owns 30,396 shares of the company’s stock worth $524,000 after buying an additional 15,963 shares in the last quarter. Daiwa Securities Group Inc. grew its position in shares of Kenvue by 2.4% during the 4th quarter. Daiwa Securities Group Inc. now owns 337,334 shares of the company’s stock worth $5,819,000 after buying an additional 7,893 shares in the last quarter. Finally, Sittner & Nelson LLC grew its position in shares of Kenvue by 12.7% during the 4th quarter. Sittner & Nelson LLC now owns 11,500 shares of the company’s stock worth $208,000 after buying an additional 1,300 shares in the last quarter. Institutional investors own 97.64% of the company’s stock.

Kenvue Trading Down 0.9%

Kenvue stock opened at $17.56 on Tuesday. The stock has a 50-day moving average of $17.37 and a two-hundred day moving average of $17.49. The company has a debt-to-equity ratio of 0.67, a quick ratio of 0.70 and a current ratio of 0.98. Kenvue Inc. has a one year low of $14.02 and a one year high of $22.87. The stock has a market cap of $33.71 billion, a PE ratio of 20.65, a price-to-earnings-growth ratio of 1.34 and a beta of 0.54.

Kenvue (NYSE:KVUE) last released its quarterly earnings results on Thursday, May 7th. The company reported $0.32 EPS for the quarter, beating analysts’ consensus estimates of $0.27 by $0.05. Kenvue had a return on equity of 20.81% and a net margin of 10.61%.The company had revenue of $3.91 billion during the quarter, compared to analysts’ expectations of $3.84 billion. During the same period last year, the business posted $0.24 earnings per share. The firm’s revenue was up 4.5% compared to the same quarter last year. On average, research analysts anticipate that Kenvue Inc. will post 1.16 EPS for the current fiscal year.

Kenvue Dividend Announcement

The firm also recently declared a quarterly dividend, which was paid on Wednesday, May 27th. Shareholders of record on Wednesday, May 13th were paid a $0.2075 dividend. The ex-dividend date was Wednesday, May 13th. This represents a $0.83 dividend on an annualized basis and a yield of 4.7%. Kenvue’s dividend payout ratio (DPR) is 97.65%.

Insider Buying and Selling

In other Kenvue news, General Counsel Matthew Orlando sold 38,491 shares of the stock in a transaction dated Friday, May 8th. The stock was sold at an average price of $17.66, for a total value of $679,751.06. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Company insiders own 1.59% of the company’s stock.

Analyst Ratings Changes

KVUE has been the topic of a number of recent research reports. UBS Group dropped their price objective on Kenvue from $19.00 to $18.00 and set a “neutral” rating on the stock in a research report on Tuesday, April 7th. Canaccord Genuity Group raised their price objective on Kenvue from $17.00 to $18.00 and gave the company a “hold” rating in a research report on Wednesday, February 18th. Argus raised Kenvue to a “hold” rating in a research report on Friday, March 6th. Barclays dropped their price objective on Kenvue from $19.00 to $18.00 and set an “equal weight” rating on the stock in a research report on Tuesday, April 14th. Finally, Weiss Ratings downgraded Kenvue from a “hold (c)” rating to a “hold (c-)” rating in a research report on Friday, May 29th. One equities research analyst has rated the stock with a Strong Buy rating, three have issued a Buy rating and twelve have given a Hold rating to the stock. According to MarketBeat.com, Kenvue currently has a consensus rating of “Hold” and an average target price of $19.33.

About Kenvue

Kenvue is a consumer health company that was established as a standalone, publicly traded business after separating from Johnson & Johnson. Listed on the New York Stock Exchange under the symbol KVUE, Kenvue focuses on the development, manufacture, marketing and distribution of consumer health and personal care products across a range of categories including skin and beauty care, baby care, oral care, wound care and over‑the‑counter medicines.

The company owns and markets a portfolio of widely recognized consumer brands, including names familiar to global shoppers across retail and pharmacy channels.